article thumbnail

The “open data” movement runs aground on FOURIER

Dr. Anish Koka

Discovering discrepancies in a major published trial from the pharma-academic complex would be a boost to those seeking to force trial data to be public, and that is exactly what a group of investigators attempted to do with a major cholesterol lowering trial published in 2017. Cholesterol lowering is big business. billion dollars.

article thumbnail

Post Pandemic, US Cardiovascular Death Rate Continues Upward Trajectory

DAIC

Investigators from the US Centers for Disease Control and Prevention (CDC) and Northwestern University Feinberg School of Medicine analyzed information from more than 10 million death certificates of US adults (aged 35+ years) whose deaths occurred between 2010 and 2022.

COVID-19 117
article thumbnail

Abstract WP314: Trends in adherence to secondary prevention guidelines after stroke

Stroke Journal

These involve managing and controlling risk factors for recurrence, such as blood pressure, body mass index (BMI), low-density lipoprotein (LDL) cholesterol, glycated hemoglobin (HbA1c), smoking, alcohol consumption and physical activity.